[go: up one dir, main page]

MA32512B1 - Derive de phenanthrenone, compositions et procedes - Google Patents

Derive de phenanthrenone, compositions et procedes

Info

Publication number
MA32512B1
MA32512B1 MA33568A MA33568A MA32512B1 MA 32512 B1 MA32512 B1 MA 32512B1 MA 33568 A MA33568 A MA 33568A MA 33568 A MA33568 A MA 33568A MA 32512 B1 MA32512 B1 MA 32512B1
Authority
MA
Morocco
Prior art keywords
phenanthrenone
derivatives
compositions
processes
compounds
Prior art date
Application number
MA33568A
Other languages
Arabic (ar)
English (en)
Inventor
Paul Vincent Rucker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA32512B1 publication Critical patent/MA32512B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention porte sur des composés de formule (i) ou sur les sels de ces composés, qui sont des modulateurs du récepteur des glucocorticoïdes. Les composés et sels de l'invention sont utiles dans le traitement d'états à médiation par l'activité de récepteur des glucocorticoïdes.
MA33568A 2008-07-28 2011-01-28 Derive de phenanthrenone, compositions et procedes MA32512B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8409508P 2008-07-28 2008-07-28
PCT/IB2009/053044 WO2010013158A1 (fr) 2008-07-28 2009-07-14 Composés de phénanthrénone, compositions et procédés

Publications (1)

Publication Number Publication Date
MA32512B1 true MA32512B1 (fr) 2011-07-03

Family

ID=41037773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33568A MA32512B1 (fr) 2008-07-28 2011-01-28 Derive de phenanthrenone, compositions et procedes

Country Status (38)

Country Link
US (2) US8148409B2 (fr)
EP (1) EP2307375B1 (fr)
JP (1) JP4823397B1 (fr)
KR (1) KR101377860B1 (fr)
CN (1) CN102112446B (fr)
AP (1) AP2744A (fr)
AR (1) AR072535A1 (fr)
AU (1) AU2009278029B2 (fr)
BR (1) BRPI0917212A2 (fr)
CA (1) CA2729578C (fr)
CL (1) CL2011000141A1 (fr)
CO (1) CO6290761A2 (fr)
CR (1) CR20110012A (fr)
CU (1) CU23983B1 (fr)
DK (1) DK2307375T3 (fr)
DO (1) DOP2011000029A (fr)
EA (1) EA018024B1 (fr)
EC (1) ECSP11010795A (fr)
ES (1) ES2527137T3 (fr)
GE (1) GEP20125640B (fr)
GT (1) GT201100026A (fr)
HR (1) HRP20150021T1 (fr)
IL (1) IL210492A (fr)
MA (1) MA32512B1 (fr)
MX (1) MX2011001053A (fr)
NI (1) NI201100028A (fr)
NZ (1) NZ590559A (fr)
PE (1) PE20110559A1 (fr)
PL (1) PL2307375T3 (fr)
PT (1) PT2307375E (fr)
RS (1) RS53747B1 (fr)
SI (1) SI2307375T1 (fr)
SV (1) SV2011003821A (fr)
TW (1) TWI374878B (fr)
UA (1) UA99198C2 (fr)
UY (1) UY32011A (fr)
WO (1) WO2010013158A1 (fr)
ZA (1) ZA201101520B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120238549A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Nuclear Hormone Receptor Modulators
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (fr) 2012-12-21 2016-04-27 Abbvie Inc Modulateurs hétérocycliques des récepteurs nucléaires aux hormones

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175383B1 (fr) 1999-04-30 2018-03-14 Pfizer Products Inc. Glucocorticoide recepteur modulateurs
CA2379650C (fr) 1999-07-30 2008-09-02 Eisai Co., Ltd. Procede de preparation de sels d'addition acides inorganiques d'antibiotiques de base et oxalates intermediaires
ATE327974T1 (de) 2000-10-28 2006-06-15 Pfizer Prod Inc Modulatoren des glucocorticoid-rezeptors
EP1201660B1 (fr) 2000-10-30 2005-08-31 Pfizer Products Inc. Modulateurs des récepteurs glucocorticoides
BR0312575A (pt) * 2002-07-08 2005-05-03 Pfizer Prod Inc Moduladores do receptor de glicocorticóides
KR101278397B1 (ko) 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
CA2673137C (fr) 2006-11-21 2015-02-10 Rigel Pharmaceuticals, Inc. Promedicaments de composes de 2,4-pyrimidinediamine et leurs utilisations
CN101678120A (zh) 2006-12-05 2010-03-24 纽罗吉斯克斯公司 前药及其制备和使用方法
CA2676907C (fr) * 2007-02-02 2012-03-20 Pfizer Products Inc. Composes tricycliques et leur utilisation en tant que modulateurs des recepteurs des glucocorticoides
DK2114970T3 (da) * 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer

Also Published As

Publication number Publication date
EP2307375B1 (fr) 2014-11-19
AP2011005562A0 (en) 2011-02-28
AU2009278029A1 (en) 2010-02-04
MX2011001053A (es) 2011-04-21
KR20110022091A (ko) 2011-03-04
GT201100026A (es) 2013-12-10
SV2011003821A (es) 2011-07-28
PE20110559A1 (es) 2011-08-06
CA2729578A1 (fr) 2010-02-04
JP4823397B1 (ja) 2011-11-24
NZ590559A (en) 2011-09-30
EP2307375A1 (fr) 2011-04-13
CR20110012A (es) 2011-02-10
HK1154245A1 (en) 2012-04-13
JP2011529103A (ja) 2011-12-01
DK2307375T3 (en) 2014-12-08
WO2010013158A1 (fr) 2010-02-04
US20120157502A1 (en) 2012-06-21
UA99198C2 (ru) 2012-07-25
GEP20125640B (en) 2012-09-10
PL2307375T3 (pl) 2015-03-31
CA2729578C (fr) 2014-05-27
NI201100028A (es) 2011-08-05
US8552035B2 (en) 2013-10-08
IL210492A0 (en) 2011-03-31
TW201014823A (en) 2010-04-16
HRP20150021T1 (xx) 2015-03-27
IL210492A (en) 2015-04-30
SI2307375T1 (sl) 2015-02-27
PT2307375E (pt) 2015-01-14
EA018024B1 (ru) 2013-04-30
KR101377860B1 (ko) 2014-03-25
US20100069444A1 (en) 2010-03-18
RS53747B1 (sr) 2015-06-30
EA201100080A1 (ru) 2011-08-30
AR072535A1 (es) 2010-09-01
CU23983B1 (es) 2014-03-26
CU20110020A7 (es) 2011-12-28
US8148409B2 (en) 2012-04-03
AU2009278029B2 (en) 2012-05-03
ES2527137T3 (es) 2015-01-21
CN102112446B (zh) 2012-10-31
CO6290761A2 (es) 2011-06-20
CL2011000141A1 (es) 2011-06-17
CN102112446A (zh) 2011-06-29
AP2744A (en) 2013-09-30
ZA201101520B (en) 2011-10-26
DOP2011000029A (es) 2014-07-31
TWI374878B (en) 2012-10-21
ECSP11010795A (es) 2011-02-28
UY32011A (es) 2010-02-26
BRPI0917212A2 (pt) 2015-11-10

Similar Documents

Publication Publication Date Title
MY153057A (en) Tryclic compounds,compositions and methods
CY1119780T1 (el) Παραγωγα πυραζολινοδιονης σαν αναστολεις της οξειδασης nadph
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
MY151246A (en) Benzofuranyl derivatives
CY1115952T1 (el) Παραγωγα πυραζολο πυριδινης σαν αναστολεις της οξειδασης nadρη
JO2910B1 (en) Organic compounds
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
EA201001639A1 (ru) Композиции и способы их получения и применения
MA33028B1 (fr) Compositions et utilisations associees
GEP20146003B (en) Benzothiazole derivatives as anticancer agents
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MA32508B1 (fr) Composes organiques
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
EA201300946A1 (ru) Асимметричные мочевины и их медицинское применение
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
MA32512B1 (fr) Derive de phenanthrenone, compositions et procedes
BRPI0606783A2 (pt) derivados de imidazol
ATE526972T1 (de) Kaliumkanalhemmer